HP cohorts, MAD
TG, SAD
Reductions in TGs were substantial and sustained. Median percentage TG change from baseline to day 113 ranged from −62.2% to −72.0% for the 100-mg and 300-mg doses, respectively, compared to an increase of 23.8% for the SAD pooled placebo (Supplementary Table After a repeat dose of ARO-ANG3, the mean (s.d.) percentage change from baseline in non-HDL-C at day 113 ranged from −41.4% (5.5%) to −49.0% (14.6%) for the 100-mg and 200-mg doses, respectively, compared to an increase of 8.6% (16.1%) for the SAD pooled placebo cohort (Supplementary Table Across all active treatment cohorts, mean (s.d.) LDL-C decreased and remained below baseline levels until day 113. At day 113, LDL-C mean percentage change from baseline ranged from −34.4% (9.6%) to −44.5% (18.1%) for the 300-mg and 200-mg doses, respectively, compared to an increase of 8.5% (27.5%) for the SAD pooled placebo cohort (Supplementary Table Mean (s.d.) percentage change from baseline in HDL-C at day 113 ranged from −14.1% (19.4%) to −37.2% (18.3%) for the 100-mg and 300-mg doses, respectively, compared to 6.4% (12.9%) in the SAD pooled placebo cohort (Supplementary Table For exploratory purposes, we compared the MAD group to the pooled placebo from the SAD group by assuming no impact in pharmacodynamics with different dosing frequency for placebo participants. Results from this post hoc MMRM analysis for ANGPTL3, TG, non-HDL-C, VLDL-C, LDL-C, HDL-C and ApoB at day 113 are presented in Extended Data Table 